Turing Medical, a leader in precision brain mapping and targeting technologies, has appointed Kevin King as its new President and Chief Executive Officer. King, who previously served as CEO of iRhythm Technologies, Affymetrix, and Thomson Reuters Healthcare, brings over three decades of experience in precision medicine and diagnostic technologies to accelerate the company's expansion plans.
"Bringing Kevin King on as CEO marks a defining moment for Turing," said Nico Dosenbach, co-founder of Turing Medical. "As CEO of iRhythm, Kevin built one of the most successful digital health companies of our time—changing the standard of care for millions living with heart conditions. His track record of turning bold ideas into widely adopted clinical solutions makes him the ideal leader to help Turing redefine how we treat serious brain disorders."
Advancing Treatment for Resistant Depression
A key initiative under King's leadership will be launching a clinical trial of Turing's pioneering PACE (Personalized Adaptive Cortical Electro-stimulation) Therapy for Treatment Resistant Depression. This innovative approach combines the precise targeting capabilities of the company's Bullsai platform with a novel minimally invasive neuromodulation therapy designed specifically for patients who haven't responded to conventional treatments.
Treatment resistant depression affects approximately 30% of patients diagnosed with major depressive disorder, representing a significant unmet medical need. Current approaches often fail to provide sustainable relief, highlighting the importance of new therapeutic modalities.
Technological Breakthroughs in Brain Mapping
Turing Medical is developing advanced functional connectivity MRI processing techniques that generate highly detailed, personalized circuit maps of the brain. These maps have the potential to transform understanding and treatment of various neurological and psychiatric disorders.
The company recently received FDA 510(k) clearance for its Bullsai platform—an automated cloud-based system that delivers individual brain maps to support neurosurgical planning. Since 2022, Turing has also successfully marketed its FIRMM and FIRMM-pix MRI motion monitoring software solutions to clinical and research customers.
Extensive Leadership Experience
King's appointment brings valuable experience in scaling healthcare technology companies. At iRhythm Technologies (NASDAQ: IRTC), he guided the organization from early-stage startup through a successful public offering. His previous roles include serving as CEO of Affymetrix Inc. (now part of Thermo Fisher Scientific) and Thomson Reuters Healthcare.
Notably, King also held senior executive positions in MRI at GE Healthcare and began his career in HP's Medical Products Group—experience particularly relevant to Turing's focus on advanced MRI processing techniques.
"Turing Medical is poised to revolutionize neuroscience and bring hope to millions suffering from devastating neuropsychiatric disorders," declared King. "The innovative technology developed by Nico Dosenbach and Damien Fair represents the culmination of their lifelong scientific mission. I'm profoundly inspired to help translate their visionary work into transformative therapies that will fundamentally change how we treat brain disorders—potentially restoring lives once thought irrevocably altered by disease."
The Future of Precision Neurotechnology
Turing Medical positions itself at the forefront of precision neurotechnology, developing solutions aimed at transforming treatment approaches for neurological and psychiatric disorders. The company's focus on minimally invasive approaches reflects the growing trend toward less intrusive yet highly effective treatment modalities in neuroscience.
With King's appointment, Turing Medical signals its readiness to move from technological development to clinical application, potentially creating new standards of care for conditions that have traditionally been difficult to treat effectively.
